Literature DB >> 20664330

Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Sandra D Comer1, Warren K Bickel, Richard Yi, Harriet de Wit, Stephen T Higgins, Galen R Wenger, Chris-Ellyn Johanson, Mary Jeanne Kreek.   

Abstract

A symposium held at the 50th annual meeting of the Behavioral Pharmacology Society in May 2007 reviewed progress in the human behavioral pharmacology of drug abuse. Studies on drug self-administration in humans are reviewed that assessed reinforcing and subjective effects of drugs of abuse. The close parallels observed between studies in humans and laboratory animals using similar behavioral techniques have broadened our understanding of the complex nature of the pharmacological and behavioral factors controlling drug self-administration. The symposium also addressed the role that individual differences, such as sex, personality, and genotype play in determining the extent of self-administration of illicit drugs in human populations. Knowledge of how these factors influence human drug self-administration has helped validate similar differences observed in laboratory animals. In recognition that drug self-administration is but one of many choices available in the lives of humans, the symposium addressed the ways in which choice behavior can be studied in humans. These choice studies in human drug abusers have opened up new and exciting avenues of research in laboratory animals. Finally, the symposium reviewed behavioral pharmacology studies conducted in drug abuse treatment settings and the therapeutic benefits that have emerged from these studies.

Entities:  

Mesh:

Year:  2010        PMID: 20664330      PMCID: PMC2913311          DOI: 10.1097/FBP.0b013e32833bb9f8

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  228 in total

1.  Self-administration of psychomotor stimulant drugs: the effects of unlimited access.

Authors:  C E Johanson; R L Balster; K Bonese
Journal:  Pharmacol Biochem Behav       Date:  1976-01       Impact factor: 3.533

2.  An experimental outline for building and exploring multi-operant behavior repertoires.

Authors:  J D FINDLEY
Journal:  J Exp Anal Behav       Date:  1962-01       Impact factor: 2.468

3.  Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene.

Authors:  Gavin Bart; K Steven LaForge; Lisa Borg; Charles Lilly; Ann Ho; Mary Jeanne Kreek
Journal:  Neuropsychopharmacology       Date:  2006-06-21       Impact factor: 7.853

4.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

5.  An experimental approach to treating chronic alcoholism: a case study and one-year follow-up.

Authors:  R Pickens; G Bigelow; R Griffiths
Journal:  Behav Res Ther       Date:  1973-08

6.  Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.

Authors:  Eric C Strain; David E Moody; Kenneth B Stoller; Sharon L Walsh; George E Bigelow
Journal:  Drug Alcohol Depend       Date:  2004-04-09       Impact factor: 4.492

7.  History of abuse liability testing in humans.

Authors:  D R Jasinski
Journal:  Br J Addict       Date:  1991-12

8.  Morphine: conditioned increases in self-administration in rhesus monkeys.

Authors:  S R Goldberg; J H Woods; C R Schuster
Journal:  Science       Date:  1969-12-05       Impact factor: 47.728

9.  Contingent reinforcement for carbon monoxide reduction: within-subject effects of pay amount.

Authors:  M L Stitzer; G E Bigelow
Journal:  J Appl Behav Anal       Date:  1984

10.  Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.

Authors:  Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

View more
  11 in total

1.  Emotional traits predict individual differences in amphetamine-induced positive mood in healthy volunteers.

Authors:  Matthew G Kirkpatrick; Nicholas I Goldenson; Nahel Kapadia; Christopher W Kahler; Harriet de Wit; Robert M Swift; John E McGeary; Steve Sussman; Adam M Leventhal
Journal:  Psychopharmacology (Berl)       Date:  2015-10-02       Impact factor: 4.530

Review 2.  A review of human drug self-administration procedures.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

Review 3.  Individual differences and social influences on the neurobehavioral pharmacology of abused drugs.

Authors:  M T Bardo; J L Neisewander; T H Kelly
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

4.  Personality and the acute subjective effects of d-amphetamine in humans.

Authors:  Matthew G Kirkpatrick; Chris-Ellyn Johanson; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2013-01-23       Impact factor: 4.153

5.  Pharmacogenetics of stimulant abuse liability: association of CDH13 variant with amphetamine response in a racially-heterogeneous sample of healthy young adults.

Authors:  Adam M Leventhal; Matthew G Kirkpatrick; Mollie S Pester; John E McGeary; Robert M Swift; Steve Sussman; Christopher W Kahler
Journal:  Psychopharmacology (Berl)       Date:  2016-10-22       Impact factor: 4.530

Review 6.  The pharmacogenetics of alcohol use disorder.

Authors:  Jermaine D Jones; Sandra D Comer; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-02-19       Impact factor: 3.455

7.  A Brief Introduction to Human Behavioral Pharmacology: Methods, Design Considerations and Ethics.

Authors:  William W Stoops
Journal:  Perspect Behav Sci       Date:  2022-03-01

8.  The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects.

Authors:  Jermaine D Jones; Mudassir Mumtaz; Nehal P Vadhan; Suky Martinez; Satadru Pramanik; Jeanne Manubay; Shanthi Mogali; Freymon Perez; Felipe Castillo; Henry R Kranzler; Sandra D Comer
Journal:  Behav Pharmacol       Date:  2022-04-12       Impact factor: 2.277

9.  Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.

Authors:  Jermaine D Jones; Taylor Speer; Sandra D Comer; Stephen Ross; John Rotrosen; Malcolm S Reid
Journal:  Am J Drug Alcohol Abuse       Date:  2013-03       Impact factor: 3.829

Review 10.  Glial and neuroinflammatory targets for treating substance use disorders.

Authors:  Ryan K Bachtell; Jermaine D Jones; Keith G Heinzerling; Patrick M Beardsley; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2017-08-31       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.